All In Biotech

Drug Trial Radar · NCT07422675

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients With Parkinson's Disease and Motor Fluctuations

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Serina TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.

Conditions

  • PARKINSON DISEASE (Disorder)
  • Advanced Parkinson's Disease

Interventions

  • SER-252 (PEOZ-apomorphine)Drug

    SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product.

  • enFuseDevice

    The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).
  2. Incidence of Moderate or Severe TEAEs Related to Study InterventionTime frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).
  3. Incidence of Serious Adverse Events (SAEs), including suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From first dose through Day 44 (30 days after the Day 14 end-of-participation visit).
  4. Change from Baseline in Vital SignsTime frame: Baseline to Day 8 (with Day 14 follow-up vitals also collected)
  5. Area under the concentration-time curve (AUC0-24, AUC0-96, AUC0-∞)Time frame: Day 1 through Day 8 (0-168 hours post-dose)
  6. Change from Baseline in Corrected QT Interval (QTcF)Time frame: Baseline to Day 8 (with Day 14 safety follow-up ECGs).
  7. Time to Maximum Plasma Concentration (Tmax)Time frame: Day 1 through Day 8 (0-168 hours post-dose).
  8. Change from Baseline in Clinical Laboratory ParametersTime frame: Baseline to Day 8 (laboratories at safety follow-up only if needed to follow up abnormalities).
  9. Fluctuation Index (FI)Time frame: Day 1 through Day 8 (0-168 hours)
  10. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)Time frame: Screening/Day -1 and Day 8.
  11. Trough Concentration (Ctrough)Time frame: Days 2-8 (24-168 hours post-dose).
  12. Coefficient of Variation (CV%) for ExposureTime frame: Day 1 through Day 8 (0-168 hours).
  13. Distributional Half-Life (h)Time frame: Day 1 through Day 8
  14. Maximum Plasma Concentration (Cmax)Time frame: Day 1 through Day 8 (0-168 hours post-dose)

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Clinical Research

    Englewood, Colorado · Recruiting

  • Velocity Clinical Research

    Hallandale, Florida · Recruiting

  • K2 Medical Research LLC

    Maitland, Florida · Recruiting

  • Quest Research Institute

    Farmington Hills, Michigan · Recruiting

  • Inland Northwest Research

    Spokane, Washington · Recruiting

  • CMAX

    Adelaide, South Australia, Australia · Recruiting

  • Monash

    Melbourne, Victoria, Australia · Completed

  • Shaung Ho Hospital - Clinical Research Center

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.